Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data

SIMPLE SUMMARY: Lung cancer is the leading cause of cancer-related death in the United States (US), and real-world studies are needed to understand effectiveness of cancer therapies for patients treated outside of cancer clinical trials. Pembrolizumab, an immunotherapy agent that aids the body’s imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Velcheti, Vamsidhar, Hu, Xiaohan, Li, Yeran, El-Osta, Hazem, Pietanza, M. Catherine, Burke, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870405/
https://www.ncbi.nlm.nih.gov/pubmed/35205788
http://dx.doi.org/10.3390/cancers14041041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870405/
https://www.ncbi.nlm.nih.gov/pubmed/35205788
http://dx.doi.org/10.3390/cancers14041041

Ejemplares similares